Altered Human CYP3A4 Activity Caused by Antley-Bixler Syndrome-Related Variants of NADPH-Cytochrome P450 Oxidoreductase Measured in a Robust In Vitro System

被引:26
|
作者
Moutinho, Daniela [1 ]
Marohnic, Christopher C. [2 ]
Panda, Satya P. [2 ]
Rueff, Jose [1 ]
Masters, Bettie Sue [2 ]
Kranendonk, Michel [1 ]
机构
[1] Univ Nova Lisboa, Ctr Invest Genet Mol Humana, Fac Med Sci, Dept Genet, P-1349008 Lisbon, Portugal
[2] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA
基金
美国国家卫生研究院;
关键词
HUMAN LIVER-MICROSOMES; ESCHERICHIA-COLI; GENETIC-VARIANTS; DRUG-METABOLISM; P-450; REDUCTASE; TESTER STRAIN; MUTATIONS; MODULATION; PHARMACOGENOMICS; STEROIDOGENESIS;
D O I
10.1124/dmd.111.042820
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
NADPH-cytochrome P450 oxidoreductase (CYPOR) variants have been described in patients with perturbed steroidogenesis and sexual differentiation, related to Antley-Bixler syndrome (ABS). It is important to determine the effect of these variants on CYP3A4, the major drug-metabolizing cytochrome P450 (P450) in humans. In this study, 12 CYPOR_ABS variants were separately coexpressed with CYP3A4 in a robust in vitro system to evaluate the effects of these variants on CYP3A4 activity in a milieu that recapitulates the stoichiometry of the mammalian systems. Full-length CYPOR variants were coexpressed with CYP3A4, resulting in relative expression levels comparable to those found in hepatic tissue. Dibenzylfluorescein (DBF), a CYP3A-specific reporter substrate (Biopharm Drug Dispos 24:375-384, 2003), was used to compare the variants and wild-type (WT) CYPOR activities with that of human liver microsomes. CYP3A4, combined with WT CYPOR, demonstrated kinetic parameters (k(cat) and K-m) equal to those for pooled human liver microsomes. CYPOR variants Y181D, Y459H, V492E, L565P, and R616X all demonstrated maximal loss of CYP3A4 catalytic efficiency, whereas R457H and G539R retained similar to 10 and 30% activities, respectively. Conversely, variants P228L, M263V, A287P, and G413S each showed WT-like capacity (k(cat)/K-m), with the A287P variant being formerly reported to exhibit substantially lower catalytic efficiency. In addition, Q153R exhibited 60% of WT CYPOR capacity to support the DBF O-debenzylation reaction, contradicting increased catalytic efficiency (k(cat)/K-m) relative to that for the WT, reported previously. Our data indicate the importance of use of simulated, validated in vitro systems, employing full-length proteins with appropriate stoichiometric incorporation of protein partners, when pharmacogenetic predictions are to be made for P450-mediated biotransformation.
引用
收藏
页码:754 / 760
页数:7
相关论文
共 37 条
  • [21] Co-expression of human cytochrome P4501A1 (CYP1A1) variants and human NADPH-cytochrome P450 reductase in the baculovirus/insect cell system
    Schwarz, D
    Kisselev, P
    Honeck, H
    Cascorbi, I
    Schunck, WH
    Roots, I
    XENOBIOTICA, 2001, 31 (06) : 345 - 356
  • [22] Cytochrome b5 Is a Major Determinant of Human Cytochrome P450 CYP2D6 and CYP3A4 Activity In Vivo
    Henderson, Colin J.
    McLaughlin, Lesley A.
    Scheer, Nico
    Stanley, Lesley A.
    Wolf, C. Roland
    MOLECULAR PHARMACOLOGY, 2015, 87 (04) : 733 - 739
  • [23] Topological changes in the CYP3A4 active site probed with phenyldiazene: Effect of interaction with NADPH-cytochrome P450 reductase and cytochrome B5 and of site-directed mutagenesis
    Yamaguchi, Y
    Khan, KK
    He, YA
    He, YQ
    Halpert, JR
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (01) : 155 - 161
  • [24] Role of NADPH-Cytochrome P450 Reductase and Cytochrome-b5/NADH-b5 Reductase in Variability of CYP3A Activity in Human Liver Microsomes
    Gan, Lu
    von Moltke, Lisa L.
    Trepanier, Lauren A.
    Harmatz, Jerold S.
    Greenblatt, David J.
    Court, Michael H.
    DRUG METABOLISM AND DISPOSITION, 2009, 37 (01) : 90 - 96
  • [25] Studies on the interactions between drugs and estrogen:: Analytical method for prediction system of gynecomastia induced by drugs on the inhibitory metabolism of estradiol using Escherichia coli coexpressing human CYP3A4 with human NADPH-cytochrome P450 reductase
    Satoh, T
    Fujita, K
    Munakata, H
    Itoh, S
    Nakamura, K
    Kamataki, T
    Itoh, S
    Yoshizawa, I
    ANALYTICAL BIOCHEMISTRY, 2000, 286 (02) : 179 - 186
  • [26] Expression and enzyme activity of cytochrome P450 enzymes CYP3A4 and CYP3A5 in human skin and tissue-engineered skin equivalents
    Smith, Sarah A.
    Colley, Helen E.
    Sharma, Parveen
    Slowik, Klaudia M.
    Sison-Young, Rowena
    Sneddon, Andrew
    Webb, Steven D.
    Murdoch, Craig
    EXPERIMENTAL DERMATOLOGY, 2018, 27 (05) : 473 - 475
  • [27] In Vitro Human Cytochrome P450 Isozymes (CYPs) Inhibition of Epifriedelanol on CYP2C9, CYP2E1 and CYP3A4
    Yu, Jie
    Zou, Fengxian
    Zhao, Lifang
    LATIN AMERICAN JOURNAL OF PHARMACY, 2022, 41 (08): : 1677 - 1683
  • [28] Effect of 95% Ethanol Khat Extract and Cathinone on in vitro Human Recombinant Cytochrome P450 (CYP) 2C9, CYP2D6, and CYP3A4 Activity
    Lim, Sharoen Yu Ming
    Azidin, Athira Rafhana Binti
    Ung, Yee Tze
    Al-Shagga, Mustafa
    Alshawsh, Mohammed Abdullah
    Mohamed, Zahurin
    Ong, Chin Eng
    Pan, Yan
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2019, 44 (03) : 423 - 431
  • [29] Effect of 95% Ethanol Khat Extract and Cathinone on in vitro Human Recombinant Cytochrome P450 (CYP) 2C9, CYP2D6, and CYP3A4 Activity
    Sharoen Yu Ming Lim
    Athira Rafhana Binti Azidin
    Yee Tze Ung
    Mustafa Al-Shagga
    Mohammed Abdullah Alshawsh
    Zahurin Mohamed
    Chin Eng Ong
    Yan Pan
    European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44 : 423 - 431
  • [30] An NH2-terminal truncated cytochrome P450 CYP3A4 showing catalytic activity is present in the cytoplasm of human liver cells
    Songhee Jeon
    Keon-Hee Kim
    Chul-Ho Yun
    Boo-Whan Hong
    Yoon-Seok Chang
    Ho-Seong Han
    Yoo-Seok Yoon
    Won-Bum Choi
    Soyun Kim
    Ai-Young Lee
    Experimental & Molecular Medicine, 2008, 40 : 254 - 260